HEALTH.2012.1.4-4
HEALTH.2012.1.4-4
4 projects · €23,487,706 total EU contribution (project-level) · 49 participating organizations · 13 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€23,487,706
Countries active
Participant organizations by country (headquarters in CORDIS).
- UK (16)
- Germany (7)
- France (5)
- Italy (4)
- SE (4)
- Spain (3)
- Netherlands (3)
- AT (1)
- BE (1)
- CH (1)
- FI (1)
- HU (1)
- US (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- AmBTU2 projects · NL
- UNIVERSITY COLLEGE LONDON2 projects · —
- UCLH2 projects · UK
- 3P1 projects · ES
- ADAPTIM1 projects · UK
- AIM1 projects · FR
- PEI1 projects · DE
- CNRS1 projects · FR
- CRL1 projects · UK
- IDIBAPS-CERCA1 projects · ES
- C.R.I.S1 projects · BE
- ERASMUS MC1 projects · NL
Projects
Page 1 of 1
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
Does vascular endothelial growth factor gene therapy safely improve outcome in severe early-onset fetal growth restriction? EVERREST · 305823 | FP7 | €5,998,984 | €7,754,709 | Details |
Transposon-based, targeted ex vivo gene therapy to treat age-related macular degeneration (AMD) TARGETAMD · 305134 | FP7 | €5,976,298 | €7,772,860 | Details |
A phase I/IIa clinical trial in Duchenne muscular dystrophy using systemically delivered morpholino antisense oligomer to skip exon 53 SKIP-NMD · 305370 | FP7 | €5,512,424 | €7,527,839 | Details |
Adoptive engineered T cell Trials to Achieve Cancer Killing ATTACK · 305863 | FP7 | €6,000,000 | €8,260,834 | Details |